Which treatment modality should we choose for advanced hepatocellular carcinoma?

Do-Young KIM

Which treatment modality should we choose for advanced hepatocellular carcinoma? / 대한간학회지

Do-Young KIM.

The Korean Journal of Hepatology ; : 353-354, 2010.

Article in English | WPRIM | ID: wpr-8335

ABSTRACT

ABSTRACT

No abstract available.

Subject(s)

Adult; Aged; Humans; Middle Aged; Antineoplastic Agents/administration & dosage; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates/administration & dosage; Carcinoma, Hepatocellular/mortality; Chemoembolization, Therapeutic; Cisplatin/administration & dosage; Fluorouracil/administration & dosage; Infusions, Intra-Arterial; Liver Neoplasms/mortality; Pyridines/administration & dosage; Survival Rate

Hepatocellular carcinoma; Transarterial chemoembolization; Hepatic arterial infusion chemotherapy

Fulltext

XML

Search on Google

Full text: Available Index: WPRIM (Western Pacific) Main subject: Pyridines / Benzenesulfonates / Infusions, Intra-Arterial / Antineoplastic Combined Chemotherapy Protocols / Survival Rate / Cisplatin / Chemoembolization, Therapeutic / Carcinoma, Hepatocellular / Fluorouracil / Liver Neoplasms Limits: Adult / Aged / Humans Language: English Journal: The Korean Journal of Hepatology Year: 2010 Type: Article

Similar

MEDLINE

LILACS

LIS

Fulltext

XML

Search on Google